Sglt2 inhibitor—dapagliflozin attenuates diabetes-induced renal injury by regulating inflammation through a cyp4a/20-hete signaling mechanism

HIGHLIGHTS

• who: Batoul Dia et al. from the Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of, Riad El Solh, have published the paper: SGLT2 Inhibitoru2014Dapagliflozin Attenuates Diabetes-Induced Renal Injury by Regulating Inflammation through a CYP4A/20-HETE Signaling Mechanism, in the Journal: Pharmaceutics 2023, 965 of /2023/
• what: This study shows that dapagliflozin treatment attenuates renal injury observed in type 2 diabetic mice. The authors determine the renoprotective effect of dapagliflozin in a high-fat diet (HFD) streptozotocin (STZ)-induced T2DM mouse model. Age-matched male C75BL/6 mice . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.